Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nazik Elmalaika Husain, Abdallah Tarig Hassan, Wadie M Elmadhoun & Mohamed H Ahmed. (2015) Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?. Expert Opinion on Drug Safety 14:9, pages 1445-1455.
Read now
Read now
John Strony, Bo Yang, Mary E. Hanson & Enrico P. Veltri. (2008) Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Current Medical Research and Opinion 24:11, pages 3149-3157.
Read now
Read now
Hyo-Soo Kim, Yangfeng Wu, Shing-Jong Lin, Chaicharn Deerochanawong, Robaayah Zambahari, Liancheng Zhao, Qiaoyi Zhang & Peter Yan. (2008) Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Current Medical Research and Opinion 24:7, pages 1951-1963.
Read now
Read now
Articles from other publishers (20)
Ibadete Bytyçi, Peter E Penson, Dimitri P Mikhailidis, Nathan D Wong, Adrian V Hernandez, Amirhossein Sahebkar, Paul D Thompson, Mohsen Mazidi, Jacek Rysz, Daniel Pella, Željko Reiner, Peter P Toth & Maciej Banach. (2022) Prevalence of statin intolerance: a meta-analysis. European Heart Journal 43:34, pages 3213-3223.
Crossref
Crossref
Jong Seo Yoon & Il Tae Hwang. (2022) Screening and Management for Dyslipidemia in Korean Children and Adolescents. The Ewha Medical Journal 45:3.
Crossref
Crossref
Jung Sub Lim, Eun Young Kim, Jae Hyun Kim, Jae-Ho Yoo, Kyung Hee Yi, Hyun Wook Chae, Jin-Ho Choi, Ji Young Kim & Il Tae Hwang. (2020) 2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents. Annals of Pediatric Endocrinology & Metabolism 25:4, pages 199-207.
Crossref
Crossref
Jung Sub Lim, Eun Young Kim, Jae Hyun Kim, Jae-Ho Yoo, Kyung Hee Yi, Hyun Wook Chae, Jin-Ho Choi, Ji Young Kim & Il Tae Hwang. (2020) 2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents. Clinical and Experimental Pediatrics 63:12, pages 454-462.
Crossref
Crossref
Cong Ai, Shanshan Zhang, Qiao He & Jingpu Shi. (2018) Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids in Health and Disease 17:1.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
222
225
.
Stephen P Adams, Michael Tsang & James M Wright. (2015) Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Jung Sub Lim. (2013) The current state of dyslipidemia in Korean children and adolescents and its management in clinical practice. Annals of Pediatric Endocrinology & Metabolism 18:1, pages 1.
Crossref
Crossref
Stephen P Adams, Michael Tsang & James M Wright. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
J.K. Aronson. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
803
826
.
Jacqueline Dunbar-Jacob, Martin P. Houze, Cameron Kramer, Faith Luyster & Maura McCall. 2010. Handbook of Behavioral Medicine. Handbook of Behavioral Medicine
83
95
.
Manfredi Rizzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis 204:2, pages 330-333.
Crossref
Crossref
György Paragh, Gyula Pados, László Márk, István Karádi, Mária Audikovszky, Károly Zámolyi & László Romics. (2008) To What Extent are National Cardiovascular Disease Preventive Guidelines Accomplished in Hungary? The Goal Attainment Program (GAP). Hungarian Medical Journal 2:4, pages 593-602.
Crossref
Crossref
John Strony, Robert Hoffman, Mary Hanson & Enrico Veltri. (2008) Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients. Clinical Therapeutics 30:12, pages 2280-2297.
Crossref
Crossref
Scott E. Conard, Harold E. Bays, Lawrence A. Leiter, Steven R. Bird, Joseph Rubino, Robert S. Lowe, Joanne E. Tomassini & Andrew M. Tershakovec. (2008) Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.. The American Journal of Cardiology 102:11, pages 1489-1494.
Crossref
Crossref
J.E. Pflumm, T. Pomykaj & M.P. Heintzen. (2008) Sekundärprävention nach MyokardinfarktSecondary prevention after myocardial infarction. Der Internist 49:9, pages 1052-1060.
Crossref
Crossref
Karim El Harchaoui, Fatima Akdim, Erik S G Stroes, Mieke D Trip & John J P Kastelein. (2008) Current and Future Pharmacologic Options for the Management of Patients Unable to Achieve Low-Density Lipoprotein-Cholesterol Goals with Statins. American Journal of Cardiovascular Drugs 8:4, pages 233-242.
Crossref
Crossref
M. Florentin, E. N. Liberopoulos & M. S. Elisaf. (2007) Ezetimibe-associated adverse effects: what the clinician needs to know. International Journal of Clinical Practice 62:1, pages 88-96.
Crossref
Crossref
. (2007) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:1.
Crossref
Crossref
Gy??rgy Paragh, L??szlo M??rk, K??roly Z??molyi, Gyula Pados & P??ter Ofner. (2007) Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary. Clinical Drug Investigation 27:9, pages 647-660.
Crossref
Crossref